{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T23:06:51Z","timestamp":1789254411465,"version":"build-2803163510"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bcp.2026.118460","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:31:13Z","timestamp":1789054273000},"page":"118460","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["Pharmacological development of glycosylation-directed anticancer interventions: Target engagement, pharmacodynamics and therapeutic index"],"prefix":"10.1016","volume":"254","author":[{"given":"Xing","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiakang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqiao","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiusen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.bcp.2026.118460_b0005","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/nrm4073","article-title":"Glycosylation-directed quality control of protein folding","volume":"16","author":"Xu","year":"2015","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118460_b0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10719-022-10041-3","article-title":"Role of glycosyltransferases in carcinogenesis; growth factor signaling and EMT\/MET programs","volume":"39","author":"Takahashi","year":"2022","journal-title":"Glycoconj. J."},{"issue":"5","key":"10.1016\/j.bcp.2026.118460_b0015","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41419-018-0522-0","article-title":"O-GlcNAc elevation through activation of the hexosamine biosynthetic pathway enhances cancer cell chemoresistance","volume":"9","author":"Liu","year":"2018","journal-title":"Cell Death Dis."},{"issue":"11","key":"10.1016\/j.bcp.2026.118460_b0020","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41576-020-0247-7","article-title":"Discovering and validating cancer genetic dependencies: approaches and pitfalls","volume":"21","author":"Lin","year":"2020","journal-title":"Nat. Rev. Genet."},{"issue":"2","key":"10.1016\/j.bcp.2026.118460_b0025","first-page":"251","article-title":"Validating cancer drug targets through chemical genetics","volume":"1806","author":"Burkard","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"issue":"17","key":"10.1016\/j.bcp.2026.118460_b0030","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1158\/0008-5472.CAN-18-0505","article-title":"Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors","volume":"78","author":"Lopez Sambrooks","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.118460_b0035","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-026-08758-y","article-title":"Tumor glycosylation in cancer therapy: biomarkers, resistance states, and translational opportunities","author":"Jin","year":"2026","journal-title":"J. Transl. Med."},{"issue":"4","key":"10.1016\/j.bcp.2026.118460_b0040","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14040911","article-title":"Glycans as Targets for Drug delivery in Cancer","volume":"14","author":"Diniz","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"19","key":"10.1016\/j.bcp.2026.118460_b0045","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910577","article-title":"Glycan-Lectin Interactions in Cancer and Viral Infections and how to Disrupt Them","volume":"22","author":"Kremsreiter","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.bcp.2026.118460_b0050","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/s41589-020-0622-x","article-title":"Targeted glycan degradation potentiates the anticancer immune response in vivo","volume":"16","author":"Gray","year":"2020","journal-title":"Nat. Chem. Biol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118460_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2025.05.005","article-title":"Redundancy of the OST catalytic subunit facilitates therapeutic targeting of N-glycosylation","volume":"32","author":"Baro","year":"2025","journal-title":"Cell Chem. Biol."},{"issue":"12","key":"10.1016\/j.bcp.2026.118460_b0060","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nchembio.2194","article-title":"Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells","volume":"12","author":"Lopez-Sambrooks","year":"2016","journal-title":"Nat. Chem. Biol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118460_b0065","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.039602","article-title":"Selective inhibition of N-linked glycosylation impairs receptor tyrosine kinase processing","volume":"12","author":"Klaver","year":"2019","journal-title":"Dis. Model. Mech."},{"issue":"2","key":"10.1016\/j.bcp.2026.118460_b0070","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1158\/1078-0432.CCR-18-0792","article-title":"Oligosaccharyltransferase Inhibition Reduces Receptor Tyrosine Kinase Activation and Enhances Glioma Radiosensitivity","volume":"25","author":"Baro","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118460_b0075","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12915-019-0671-3","article-title":"Fueling the fire: emerging role of the hexosamine biosynthetic pathway in cancer","volume":"17","author":"Akella","year":"2019","journal-title":"BMC Biol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118460_b0080","doi-asserted-by":"crossref","first-page":"e785","DOI":"10.1002\/ctm2.785","article-title":"And-1 O-GlcNAcylation regulates homologous recombination repair and radioresistance in colorectal cancer","volume":"12","author":"Zhou","year":"2022","journal-title":"Clin. Transl. Med."},{"issue":"7","key":"10.1016\/j.bcp.2026.118460_b0085","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202256458","article-title":"O-GlcNAcylation promotes topoisomerase II\u03b1 catalytic activity in breast cancer chemoresistance","volume":"24","author":"Liu","year":"2023","journal-title":"EMBO Rep."},{"issue":"8","key":"10.1016\/j.bcp.2026.118460_b0090","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.7150\/thno.81760","article-title":"Roles of glycosylation at the cancer cell surface: opportunities for large scale glycoproteomics","volume":"13","author":"\u010caval","year":"2023","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.bcp.2026.118460_b0095","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1007\/s11696-021-02026-7","article-title":"Glycosyltransferases as targets for therapeutic intervention in cancer and inflammation: molecular modeling insights","volume":"76","author":"Tvaro\u0161ka","year":"2022","journal-title":"Chem. Pap."},{"issue":"7","key":"10.1016\/j.bcp.2026.118460_b0100","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1349-7006.2008.00839.x","article-title":"Functional roles of N-glycans in cell signaling and cell adhesion in cancer","volume":"99","author":"Zhao","year":"2008","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bcp.2026.118460_b0105","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/bs.acr.2014.11.001","article-title":"Glycans and cancer: role of N-glycans in cancer biomarker, progression and metastasis, and therapeutics","volume":"126","author":"Taniguchi","year":"2015","journal-title":"Adv. Cancer Res."},{"issue":"9","key":"10.1016\/j.bcp.2026.118460_b0110","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2174\/138955706778195162","article-title":"Glycosylation pathways as drug targets for cancer: glycosidase inhibitors","volume":"6","author":"Gerber-Lemaire","year":"2006","journal-title":"Mini Rev. Med. Chem."},{"issue":"8","key":"10.1016\/j.bcp.2026.118460_b0115","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1039\/C4MD00086B","article-title":"Beyond substrate analogues: new inhibitor chemotypes for glycosyltransferases","volume":"5","author":"Tedaldi","year":"2014","journal-title":"MedChemComm"},{"issue":"37","key":"10.1016\/j.bcp.2026.118460_b0120","doi-asserted-by":"crossref","first-page":"10304","DOI":"10.1073\/pnas.1608069113","article-title":"Precision glycocalyx editing as a strategy for cancer immunotherapy","volume":"113","author":"Xiao","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bcp.2026.118460_b0125","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41392-025-02219-6","article-title":"N-deglycosylation targeting chimera (DGlyTAC): a strategy for immune checkpoint proteins inactivation by specifically removing N-glycan","volume":"10","author":"Li","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"669","key":"10.1016\/j.bcp.2026.118460_b0130","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj1270","article-title":"Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade","volume":"14","author":"Stanczak","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.bcp.2026.118460_b0135","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41551-024-01202-w","article-title":"Targeted desialylation and cytolysis of tumour cells by fusing a sialidase to a bispecific T-cell engager","volume":"8","author":"Yang","year":"2024","journal-title":"Nat. Biomed. Eng."},{"issue":"38","key":"10.1016\/j.bcp.2026.118460_b0140","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2300366120","article-title":"Targeted glycan degradation potentiates cellular immunotherapy for solid tumors","volume":"120","author":"Wu","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.bcp.2026.118460_b0145","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/glycob\/cwaa008","article-title":"The manifold roles of sialic acid for the biological functions of endothelial glycoproteins","volume":"30","author":"D'Addio","year":"2020","journal-title":"Glycobiology"},{"issue":"1","key":"10.1016\/j.bcp.2026.118460_b0150","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41420-024-02180-3","article-title":"Biological function of sialic acid and sialylation in human health and disease","volume":"10","author":"Zhu","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.bcp.2026.118460_b0155","doi-asserted-by":"crossref","unstructured":"Munkley J. Aberrant Sialylation in Cancer: Therapeutic Opportunities. Cancers (Basel). 2022;14(17). doi: 10.3390\/cancers14174248.","DOI":"10.3390\/cancers14174248"},{"issue":"10","key":"10.1016\/j.bcp.2026.118460_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2025.110641","article-title":"Sialic acids in cancer biology and immunity-recent advancements","volume":"301","author":"van Vliet","year":"2025","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2026.118460_b0165","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s42003-019-0642-9","article-title":"Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation","volume":"2","author":"Wang","year":"2019","journal-title":"Commun. Biol."},{"issue":"11","key":"10.1016\/j.bcp.2026.118460_b0170","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/0008-5472.CAN-19-3133","article-title":"Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity","volume":"80","author":"Sun","year":"2020","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.118460_b0175","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ccell.2018.01.009","article-title":"Eradication of Triple-negative Breast Cancer Cells by Targeting Glycosylated PD-L1","volume":"33","author":"Li","year":"2018","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bcp.2026.118460_b0180","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1021\/acs.jproteome.0c00521","article-title":"PD-L1 Glycosylation and its Impact on Binding to Clinical Antibodies","volume":"20","author":"Benicky","year":"2021","journal-title":"J. Proteome Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118460_b0185","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12929-020-00670-x","article-title":"The impact of PD-L1\u2009N-linked glycosylation on cancer therapy and clinical diagnosis","volume":"27","author":"Wang","year":"2020","journal-title":"J. Biomed. Sci."},{"issue":"5","key":"10.1016\/j.bcp.2026.118460_b0190","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41423-024-01142-0","article-title":"Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2","volume":"21","author":"Wieboldt","year":"2024","journal-title":"Cell. Mol. Immunol."},{"issue":"Pt 6","key":"10.1016\/j.bcp.2026.118460_b0195","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1042\/BST0361472","article-title":"Galectin-glycan lattices regulate cell-surface glycoprotein organization and signalling","volume":"36","author":"Garner","year":"2008","journal-title":"Biochem. Soc. Trans."},{"issue":"11","key":"10.1016\/j.bcp.2026.118460_b0200","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2215376120","article-title":"MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint","volume":"120","author":"Smith","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2026.118460_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2022.101110","article-title":"Human sialoglycan ligands for immune inhibitory Siglecs","volume":"90","author":"Gonzalez-Gil","year":"2023","journal-title":"Mol. Aspects Med."},{"issue":"12","key":"10.1016\/j.bcp.2026.118460_b0210","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1158\/2326-6066.CIR-22-0366","article-title":"Targeting the Siglec-Sialic Acid Immune Axis in Cancer: current and Future Approaches","volume":"10","author":"L\u00e4ubli","year":"2022","journal-title":"Cancer Immunol. Res."},{"issue":"4","key":"10.1016\/j.bcp.2026.118460_b0215","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.it.2020.02.001","article-title":"Sialoglycans and Siglecs can Shape the Tumor Immune Microenvironment","volume":"41","author":"van de Wall","year":"2020","journal-title":"Trends Immunol."},{"key":"10.1016\/j.bcp.2026.118460_b0220","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3389\/fonc.2016.00127","article-title":"Galectin-3 Determines Tumor Cell Adaptive strategies in Stressed Tumor Microenvironments","volume":"6","author":"Cardoso","year":"2016","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2026.118460_b0225","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1250559","article-title":"Resistance to anti-PD-1\/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1\/PD-L1","volume":"14","author":"Mabbitt","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118460_b0230","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3389\/fonc.2014.00138","article-title":"Extracellular galectin-3 in tumor progression and metastasis","volume":"4","author":"Fortuna-Costa","year":"2014","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118460_b0235","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13046-024-02968-2","article-title":"Galectin-3 and cancer immunotherapy: a glycobiological rationale to overcome tumor immune escape","volume":"43","author":"Scafetta","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bcp.2026.118460_b0240","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1053\/j.seminoncol.2016.07.002","article-title":"Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development","volume":"43","author":"Parchment","year":"2016","journal-title":"Semin. Oncol."},{"issue":"37","key":"10.1016\/j.bcp.2026.118460_b0245","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2107982118","article-title":"Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics","volume":"118","author":"Kumar","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.bcp.2026.118460_b0250","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1053\/j.seminoncol.2016.07.001","article-title":"Theory and practice of clinical pharmacodynamics in oncology drug development","volume":"43","author":"Parchment","year":"2016","journal-title":"Semin. Oncol."},{"issue":"12","key":"10.1016\/j.bcp.2026.118460_b0255","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.2174\/138945012803530062","article-title":"Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials","volume":"13","author":"Ang","year":"2012","journal-title":"Curr. Drug Targets"},{"issue":"6","key":"10.1016\/j.bcp.2026.118460_b0260","first-page":"596","article-title":"Gene expression-based pharmacodynamic biomarkers: the beginning of a new era in biomarker-driven anti-tumor drug development","volume":"10","author":"Mizuarai","year":"2010","journal-title":"Curr. Mol. Med."},{"issue":"10","key":"10.1016\/j.bcp.2026.118460_b0265","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1158\/0008-5472.CAN-07-6389","article-title":"Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells","volume":"68","author":"Contessa","year":"2008","journal-title":"Cancer Res."},{"issue":"50","key":"10.1016\/j.bcp.2026.118460_b0270","doi-asserted-by":"crossref","first-page":"34457","DOI":"10.1074\/jbc.R114.577718","article-title":"Cancer metabolism and elevated O-GlcNAc in oncogenic signaling","volume":"289","author":"Ma","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.bcp.2026.118460_b0275","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/s41580-025-00855-y","article-title":"N-glycan-dependent protein maturation and quality control in the ER","volume":"26","author":"Guay","year":"2025","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"32","key":"10.1016\/j.bcp.2026.118460_b0280","doi-asserted-by":"crossref","first-page":"24600","DOI":"10.1074\/jbc.M110.134544","article-title":"Inhibition of Golgi apparatus glycosylation causes endoplasmic reticulum stress and decreased protein synthesis","volume":"285","author":"Xu","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.bcp.2026.118460_b0285","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.tibs.2010.04.005","article-title":"O-GlcNAc signaling: a metabolic link between diabetes and cancer?","volume":"35","author":"Slawson","year":"2010","journal-title":"Trends Biochem. Sci"},{"issue":"16","key":"10.1016\/j.bcp.2026.118460_b0290","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1016\/j.jmb.2016.05.028","article-title":"O-GlcNAcylation in Cancer Biology: linking Metabolism and Signaling","volume":"428","author":"Ferrer","year":"2016","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bcp.2026.118460_b0295","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1101\/sqb.2016.81.031096","article-title":"A Pipeline for Drug Target Identification and Validation","volume":"81","author":"Manchado","year":"2016","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"issue":"12","key":"10.1016\/j.bcp.2026.118460_b0300","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nrc.2017.93","article-title":"Transport of drugs from blood vessels to tumour tissue","volume":"17","author":"Dewhirst","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.118460_b0305","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/cpt.1211","article-title":"Tumor Drug Penetration Measurements could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle","volume":"106","author":"Bartelink","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.bcp.2026.118460_b0310","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nrc1893","article-title":"Drug penetration in solid tumours","volume":"6","author":"Minchinton","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2026.118460_b0315","doi-asserted-by":"crossref","DOI":"10.5402\/2012\/590626","article-title":"Pharmacodynamic modelling of biomarker data in oncology","volume":"2012","author":"Jackson","year":"2012","journal-title":"ISRN Pharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118460_b0320","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1158\/1078-0432.CCR-18-2523","article-title":"Evaluation of Pharmacodynamic responses to Cancer Therapeutic Agents using DNA damage Markers","volume":"25","author":"Wilsker","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2026.118460_b0325","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1158\/1541-7786.MCR-18-1025","article-title":"O-GlcNAcylation Enhances Double-Strand break Repair, Promotes Cancer Cell Proliferation, and Prevents Therapy-Induced Senescence in Irradiated Tumors","volume":"17","author":"Efimova","year":"2019","journal-title":"Mol. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118460_b0330","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/bcp.12258","article-title":"Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response","volume":"79","author":"Bender","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"23","key":"10.1016\/j.bcp.2026.118460_b0335","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20236074","article-title":"A Gatekeeper of Health and Tumor Progression","volume":"20","author":"Harada","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.bcp.2026.118460_b0340","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1152\/physrev.00043.2019","article-title":"Role of O-Linked N-Acetylglucosamine Protein Modification in Cellular (Patho)Physiology","volume":"101","author":"Chatham","year":"2021","journal-title":"Physiol. Rev."},{"issue":"4","key":"10.1016\/j.bcp.2026.118460_b0345","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/glycob\/cwy093","article-title":"Oligosaccharyltransferase structures provide novel insight into the mechanism of asparagine-linked glycosylation in prokaryotic and eukaryotic cells","volume":"29","author":"Shrimal","year":"2019","journal-title":"Glycobiology"},{"issue":"7","key":"10.1016\/j.bcp.2026.118460_b0350","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nrm.2017.22","article-title":"Protein O-GlcNAcylation: emerging mechanisms and functions","volume":"18","author":"Yang","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2026.118460_b0355","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1146\/annurev-nutr-071812-161240","article-title":"O-GlcNAc cycling: a link between metabolism and chronic disease","volume":"33","author":"Bond","year":"2013","journal-title":"Annu. Rev. Nutr."},{"issue":"3","key":"10.1016\/j.bcp.2026.118460_b0360","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10863-018-9744-1","article-title":"O-GlcNAc: a novel regulator of immunometabolism","volume":"50","author":"Machacek","year":"2018","journal-title":"J. Bioenerg. Biomembr."},{"issue":"2","key":"10.1016\/j.bcp.2026.118460_b0365","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1208\/s12248-012-9436-4","article-title":"Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib","volume":"15","author":"Yamazaki","year":"2013","journal-title":"AAPS J."},{"key":"10.1016\/j.bcp.2026.118460_b0370","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3389\/fimmu.2019.01047","article-title":"Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity against Cancer","volume":"10","author":"Daly","year":"2019","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118460_b0375","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1158\/1078-0432.CCR-15-1295","article-title":"Optimal Dosing for Targeted Therapies in Oncology: Drug Development cases Leading by example","volume":"22","author":"Sachs","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"23","key":"10.1016\/j.bcp.2026.118460_b0380","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.2012.43.4233","article-title":"Maximum-tolerated dose, optimum biologic dose, or optimum clinical value: dosing determination of cancer therapies","volume":"30","author":"Marshall","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118460_b0385","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12885-021-07782-z","article-title":"Optimal biological dose: a systematic review in cancer phase I clinical trials","volume":"21","author":"Fraisse","year":"2021","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.bcp.2026.118460_b0390","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djp079","article-title":"Dose escalation methods in phase I cancer clinical trials","volume":"101","author":"Le Tourneau","year":"2009","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.bcp.2026.118460_b0395","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1144056","article-title":"Project Optimus, an FDA initiative: Considerations for cancer drug development internationally, from an academic perspective","volume":"13","author":"Murphy","year":"2023","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118460_b0400","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00280-015-2795-7","article-title":"Validation of a predictive modeling approach to demonstrate the relative efficacy of three different schedules of the AKT inhibitor AZD5363","volume":"76","author":"Yates","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118460_b0405","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1158\/2159-8290.CD-22-1401","article-title":"Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas","volume":"13","author":"Scheich","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2026.118460_b0410","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.899192","article-title":"Nascent Glycoproteome reveals that N-Linked Glycosylation Inhibitor-1 Suppresses Expression of Glycosylated Lysosome-Associated Membrane Protein-2","volume":"9","author":"Cao","year":"2022","journal-title":"Front. Mol. Biosci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118460_b0415","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41419-025-08209-4","article-title":"O-GlcNAcylation of XRCC4 controls its stability and confers resistance to DNA double-strand break damage in cancer cells","volume":"17","author":"Ko","year":"2026","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.bcp.2026.118460_b0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107141","article-title":"OGT and OGA: Sweet guardians of the genome","volume":"300","author":"Wu","year":"2024","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.118460_b0425","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1039\/C7MD00550D","article-title":"Identification of non-substrate-like glycosyltransferase inhibitors from library screening: pitfalls & hits","volume":"9","author":"Ema","year":"2018","journal-title":"Medchemcomm"},{"issue":"7","key":"10.1016\/j.bcp.2026.118460_b0430","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/mc.23170","article-title":"Saccharide analog, 2-deoxy-d-glucose enhances 4-1BB-mediated antitumor immunity via PD-L1 deglycosylation","volume":"59","author":"Kim","year":"2020","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.bcp.2026.118460_b0435","doi-asserted-by":"crossref","DOI":"10.1177\/15330338211019442","article-title":"Removal of N-Linked Glycosylation Enhances PD-L1 Detection in Colon Cancer: Validation Research based on Immunohistochemistry Analysis","volume":"20","author":"Xu","year":"2021","journal-title":"Technol. Cancer Res. Treat."},{"issue":"9","key":"10.1016\/j.bcp.2026.118460_b0440","first-page":"640","article-title":"Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer","volume":"28","author":"Adams","year":"2018","journal-title":"Glycobiology"},{"issue":"5","key":"10.1016\/j.bcp.2026.118460_b0445","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/bjd\/ljad517","article-title":"The sialic acid-Siglec immune checkpoint: an opportunity to enhance immune responses and therapy effectiveness in melanoma","volume":"190","author":"Coccimiglio","year":"2024","journal-title":"Br. J. Dermatol."},{"issue":"7","key":"10.1016\/j.bcp.2026.118460_b0450","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16071334","article-title":"Targeting Siglec-Sialylated MUC1 Immune Axis in Cancer","volume":"16","author":"Ayyalasomayajula","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.bcp.2026.118460_b0455","first-page":"369","article-title":"Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy","volume":"20","author":"Yu","year":"2023","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.bcp.2026.118460_b0460","article-title":"Inhibition of galectins in cancer: Biological challenges for their clinical application","volume":"13","author":"Laderach","year":"2022","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118460_b0465","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1093\/glycob\/cwn071","article-title":"N-Glycans in cancer progression","volume":"18","author":"Lau","year":"2008","journal-title":"Glycobiology"},{"issue":"12","key":"10.1016\/j.bcp.2026.118460_b0470","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1158\/1078-0432.CCR-07-4562","article-title":"Oncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patient","volume":"14","author":"Doroshow","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.bcp.2026.118460_b0475","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/psp4.13079","article-title":"Realizing the promise of Project Optimus: challenges and emerging opportunities for dose optimization in oncology drug development","volume":"13","author":"Gao","year":"2024","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118460_b0480","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/psp4.12602","article-title":"Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose","volume":"10","author":"Xiong","year":"2021","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"issue":"24","key":"10.1016\/j.bcp.2026.118460_b0485","doi-asserted-by":"crossref","first-page":"8184","DOI":"10.1158\/1078-0432.CCR-08-1324","article-title":"Early tumor drug pharmacokinetics is influenced by tumor perfusion but not plasma drug exposure","volume":"14","author":"Saleem","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118460_b0490","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abk2901","article-title":"Real-time monitoring of drug pharmacokinetics within tumor tissue in live animals","volume":"8","author":"Seo","year":"2022","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.bcp.2026.118460_b0495","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41416-019-0621-4","article-title":"Window of opportunity clinical trial designs to study cancer metabolism","volume":"122","author":"Aroldi","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2026.118460_b0500","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1158\/1078-0432.CCR-16-1658","article-title":"Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4\/BET Inhibitors","volume":"23","author":"Yeh","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.bcp.2026.118460_b0505","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41419-024-07131-5","article-title":"O-GlcNAcylation inhibition redirects the response of colon cancer cells to chemotherapy from senescence to apoptosis","volume":"15","author":"Loison","year":"2024","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.bcp.2026.118460_b0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112475","article-title":"Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment","volume":"42","author":"Egan","year":"2023","journal-title":"Cell Rep."},{"issue":"3","key":"10.1016\/j.bcp.2026.118460_b0515","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/cpt.3373","article-title":"Dosage Optimization: a Regulatory Perspective for developing Oncology Drugs","volume":"116","author":"Rahman","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.118460_b0520","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ccell.2019.06.006","article-title":"Glycosylation in the Era of Cancer-Targeted Therapy: where are we heading?","volume":"36","author":"Mereiter","year":"2019","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.bcp.2026.118460_b0525","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.trecan.2020.04.002","article-title":"Targeting Glycosylation: a New Road for Cancer Drug Discovery","volume":"6","author":"Costa","year":"2020","journal-title":"Trends Cancer."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226007999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226007999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T22:50:31Z","timestamp":1789253431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226007999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":105,"alternative-id":["S0006295226007999"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118460","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological development of glycosylation-directed anticancer interventions: Target engagement, pharmacodynamics and therapeutic index","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118460","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"118460"}}